Tumor targeted T cells to enhance anti-tumor efficacy and dictate umbilical cord blood (UCB) engraftment in the setting of double UCB transplant.

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1034887

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Currently, despite cord blood transplantation, most leukemia patients will ultimately die of disease relapse. Therefore, my proposal is focused on improving the effectiveness of cord blood transplantation by further infusion of gene modified umbilical cord derived immune blood cells designed to specifically target and lyse residual leukemia tumor cells. This novel approach this will decrease disease relapse and lead to better patient survival following cord blood transplant therapy.

Funded Activity Details

Start Date: 01-01-2012

End Date: 01-01-2018

Funding Scheme: Early Career Fellowships

Funding Amount: $376,002.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Applied Immunology (incl. Antibody Engineering, Xenotransplantation and T-cell Therapies)

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

T cell immunotherapy | cell therapy | cord blood | immunotherapy | transplant

Related Links